Applied Filters
Carpmaels & Ransford promotes Jennifer Antcliff to partner
European law firm Carpmaels & Ransford has promoted Jennifer Antcliff to partner in its dispute resolution team in its London office, bringing the total number of partners in the team to five.
English appeals court refuses Neurim injunction for insomnia drug
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Kymab victorious before UK Supreme Court in Regeneron appeal
The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.
EC backs voluntary COVID-19 vaccine licensing
The European Commission has backed voluntary IP licensing as part of its new vaccines strategy.
UKIPO rejects Novartis’s TM opposition attempt
Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.
Roche and Innovent unite in $2bn biospecifics deal
Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Unitary SPC should follow new patent system: EC official
The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
Monster falls short in Merck TM dispute
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA.
AG advises CJEU to uphold €94 million pay-for-delay fine
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
English court gives Mylan green-light to sell generic insomnia drug
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.
